Nymox Pharmaceutical

Nymox Pharmaceutical is a biopharmaceutical company dedicated to the development of innovative treatments and diagnostics for urological and neurological conditions. The company's flagship product, fexapotide triflutate (NX-1207), is an investigational drug administered via intraprostatic injection for the treatment of benign prostatic hyperplasia (BPH) and low-grade prostate cancer. Fexapotide works by inducing selective apoptosis in prostate glandular cells, leading to tissue shrinkage and symptom relief. Additionally, Nymox has developed AlzheimAlert, a non-invasive urinary test designed to assist in the diagnosis of Alzheimer's disease by detecting neural thread protein levels. While the company has completed extensive Phase 3 trials for BPH, it continues to navigate the regulatory approval process with the FDA and other global health authorities.